Rudin, Charles M. http://orcid.org/0000-0001-5204-3465
Article History
First Online: 25 May 2023
Competing interests
: C.M.R. has consulted about oncology drug development with AbbVie, Amgen, Astra Zeneca, D2G, Daiichi Sankyo, Epizyme, Genentech/Roche, Ipsen, Jazz, Kowa, Lilly, Merck, and Syros. He serves on the scientific advisory boards of Auron, Bridge Medicines, DISCO, Earli, and Harpoon Therapeutics.